CordenPharma Group, the global pharmaceutical service and manufacturing platform of International Chemical Investors Group (ICIG), has appointed Michael Quirmbach as chief executive officer and president, effective August 1, 2019. Dr. Quirmbach joined CordenPharma in October 2014 as chief business officer and has been a member of the executive leadership team. Since then he has been instrumental in establishing CordenPharma in the market as a contract development and manufacturing organization (CDMO) to the pharmaceutical industry.
 
Prior to joining CordenPharma, Dr. Quirmbach held several management positions in the CDMO and biotech industry with companies such as Siegfried, Dr. Reddy’s and Solvias. He will succeed Riku Rautsola, who will transition to the role of a senior advisor to the executive leadership team, in support of a smooth transition.
 
The executive leadership Team of CordenPharma Group will consist of Dr. Michael Quirmbach as CEO & President, Dr. Walter Kittl as COO, together with Heiko Serwe, CFO, and Dr. Esua Macniell, Chief Compliance Officer.
 
“We thank Riku Rautsola for taking the responsibility of CordenPharma at a critical time and are pleased with the appointment of Michael Quirmbach as our new chief executive officer and president of CordenPharma Group,” said Achim Riemann and Patrick Schnitzer, managing directors, ICIG. “Dr. Quirmbach has demonstrated strong leadership and was instrumental in CordenPharma’s continued growth trajectory over the last years to become a major CDMO player to the pharmaceutical industry. Our leadership team is now well positioned to accelerate plans for long-term growth.”